Agilent Technologies Inc.. (2/6/12). "Press Release: Agilent Technologies Adds Sub-2 µm Protein Analysis Biocolumns with C3 and Diphenyl Phases for Broader Selectivity and Better Peak Shape". Santa Clara, CA.

	Organisation	Agilent Technologies Inc. (NYSE: A)
	Group	Agilent (Group)
	Organisation 2	DNA Medical Communications (division of Weber Shandwick), London
	Group	Interpublic Group (IPG) (Group)
	Product	ZORBAX Rapid Resolution High Definition column
	Product 2	proteomics
	Index term 2	Agilent–Interpublic Group: public relations, 201202 supply service existent by DNA Medical Communications London
	Person	Matlow, Stuart (Agilent)
	Person 2	Muthada-Pottayya, Selina (Interpublic Group 201202 Assistant Account Executive at DNA Medical Communications London)

Agilent Technologies Inc. (NYSE: A) today announced it has expanded its family of sub-2 µm particle 300 Angstrom pore columns for reversed-phase liquid chromatography with rapid-resolution, high-definition ZORBAX 300SB-C3 and 300-Diphenyl 1.8 µm columns.

The columns extend the benefits of reversed-phase biomolecule separations to ultra-high-performance liquid chromatography (UHPLC). The C3 phase broadens the selectivity and improves peak shape and recovery options for larger proteins, including antibodies. The diphenyl phase offers additional selectivity through pi-pi interactions with aromatic amino acids in the primary structure.

"Agilent now offers the broadest range of sub-2 µm, wide-pore biocolumns for reversed-phase liquid chromatography," said Agilent product manager Linda Lloyd. "The new 1.8 µm columns add to the scalability of the ZORBAX family of C18, C8 and C3 phases already available with 3.5 and 5 µm particles. We're pleased to bring this higher order characterization and increased speed to UHPLC users."

The 1.8 µm particle size and 300 Angstrom pore size bring UHPLC efficiency, resolution and robust quantitation to reversed-phase protein separations. Additionally, the columns are stable up to 1200 bar. Agilent's proven StableBond technology for the C18, C8 and C3 columns, and the end-capped diphenyl with Pursuit chemistry, deliver symmetrical peaks - even at low pH - when using trifluoroacetic or formic acid mobile phase modifiers. Column life is not compromised.

The full ZORBAX rapid-resolution, high-definition family now includes 13 phases for small molecule applications, including HILIC, and four phases for large molecule separations. This broad range of options enables chromatographers to optimize their UHPLC separations with selectivity refinements. In addition, RRHD's 1200 bar stability provides increased flexibility with flow rates and mobile phase selection.

For more information, visit www.agilent.com/chem/biohplcproteins .

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications. The company's 18,700 employees serve customers in more than 100 countries. Agilent had net revenues of $6.6 billion in fiscal 2011. Information about Agilent is available at www.agilent.com.

# # #

NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.

Selina Muthada-Pottayya
Assistant Account Executive
dna medical communications
Fox Court, 14 Grays Inn Road
London, WC1X 8WS
United Kingdom
T:+44 (0)20 7067 0489
F:+44 (0)844 826 8317
SPottayya@dnamedcomms.com

Record changed: 2012-02-07

Follow Us!

Top News

Upcoming Events

Associations

Partners

Agilent Technologies Inc.. (2/6/12). "Press Release: Agilent Technologies Adds Sub-2 µm Protein Analysis Biocolumns with C3 and Diphenyl Phases for Broader Selectivity and Better Peak Shape". Santa Clara, CA.

More documents for Agilent (Group)